Research programme: glutathione-pegylated liposome therapeutics - BBB Therapeutics

Drug Profile

Research programme: glutathione-pegylated liposome therapeutics - BBB Therapeutics

Alternative Names: 2B3-XXX; Brain-targeted liposomal therapeutics - to-BBB

Latest Information Update: 03 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator to-BBB technologies; VIB
  • Developer BBB Therapeutics; VIB
  • Class Antibodies; Glucocorticoids; Hydrolases; Pregnadienetriols
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammation; Multiple sclerosis
  • Research Alzheimer's disease; Brain cancer; CNS disorders

Most Recent Events

  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 17 Dec 2013 2B3-201 entered clinical development in the Netherlands .
  • 20 Aug 2013 Active development in Neuroinflammation is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top